SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Compared with pioglitazone, SGLT2 inhibitors significantly reduced the fatty liver index, which means that SGLT2 inhibitors can be preferred drugs for T2DM patients with NAFLD.